The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohnʼs Disease Effector T Cells In Vivo

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

(2016) D. C. Baumgart et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

(2016) Aurelien Amiot et al.   Clinical Gastroenterology and Hepatology

Leukocyte Trafficking to the Small Intestine and Colon

(2016) Aida Habtezion et al.   GASTROENTEROLOGY

Integrin-based therapeutics: biological basis, clinical use and new drugs

(2016) Klaus Ley et al.   NATURE REVIEWS DRUG DISCOVERY

Integrins and adhesion molecules as targets to treat inflammatory bowel disease

(2015) Ivana Bravatà et al.   CURRENT OPINION IN PHARMACOLOGY

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo

(2015) Anika Fischer et al.   GUT

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

(2015) Emily E. Vivio et al.   Journal of Crohns & Colitis

Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease

(2015) Lianjie Lin et al.   MEDICINE

Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung

(2015) S. Schreiber et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases

(2015) Man Cai Wang et al.   MEDICINE

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

(2014) Raja Atreya et al.   NATURE MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases

(2011) Warren Strober et al.   GASTROENTEROLOGY

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

(2011) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Ulcerative Colitis

(2011) Silvio Danese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small-Intestinal Manifestations of Dextran Sulfate Sodium Consumption in Rats and Assessment of the Effects of Lactobacillus fermentum BR11

(2008) Mark S. Geier et al.   DIGESTIVE DISEASES AND SCIENCES